| CDR was established in 1986 by Professor and Chief Executive Keith Wesnes to help the pharmaceutical industry rapidly and unequivocally explore the effects of a vast array of novel and established compounds on cognitive function by providing automated cognition assessments. Over 20 years on, and now with some 50 staff, CDR remains the market leader for the provision of automated cognitive function assessments in worldwide clinical trials. Based in South Oxfordshire in the UK, in 2006 CDR was delighted to announce the opening of a second office in Chicago, USA. In 2007 CDR established itself in Australia with a base at Swinburne University of Technology, Melbourne.
In recent years, CDR has been the recipient of several awards, including Queen’s Awards, the UK's most prestigious awards for business performance, for International Trade and Innovation in 2002 and 2003 respectively, and the Investor in People award, a national quality standard for improving performance through people, in 2005. CDR is extremely proud to be recognised for its growth in overseas earnings, commercial success through innovative products and services, and for its policies in place for good management of the staff.
CDR’s gold standard cognitive testing system is highly sensitive and simple to administer, detecting both enhancements and impairments to cognition in any population in any clinical trial setting. This sensitivity, and the efficiency with which the system can be employed, makes it an ideal solution for volunteer and patient trials.
CDR’s proprietary laptop based system is validated in over 50 languages, and can be administered at the bedside or even in patients’ homes. Available through several platforms including a wristworn device, the internet, via telephone using customised ClinPhone technology, and in prototype as a PDA, this flexible range of options allows testing to be carried out in virtually any environment. The system is documented to FDA 21 CFR part 11 standards, and has been described in over 200 peer reviewed chapters and articles.
The system is able to overcome the shortfalls of non-automated tests such as time restraints, the inconvenience of one-to-one testing, and confounding of key measures. Data are electronically captured and transferred, highly reliable, and the system is able to record both speed and accuracy measures, the separation of which is vital to the definitive identification of cognitive effects.
CDR offer a full, customised cognition assessment service, implementing assessments into any trial design to virtually any timeline and providing support and consultancy throughout your study. Expert advice on appropriate measures and testing schedules, analysis, interpretation and reporting of the data are included as standard. CDR’s highly skilled research team are on hand throughout the study to respond to any requirements or queries you may have, and their unrivalled databases allow the accurate profiling of your medication to help it succeed in the marketplace.
To date, the CDR system has been used at over 2000 sites worldwide in over 900 trials involving a vast range of indications, in collaboration with over 130 sponsors including the top 17 global Pharmaceutical companies. CDR’s system has been used in every type of Phase I trial and their extensive work in patient trials has ranged from small early Phase II trials to large late phase international multicentre studies. |
 |
|
|
